1914148-72-3
Chemical Structure
Ezurpimtrostat
Synonym(s): GNS561
- CAS No.: 1914148-72-3
- Formula:C25H31ClN4
- Molecular Weight:422.99
IUPAC Name: 4-(4-(tert-butylamino)piperidin-1-yl)-N-(4-chlorobenzyl)quinolin-2-amine
InChIKey: QVXSJSXAVQJXOV-UHFFFAOYSA-N
SMILES: CC(NC1CCN(C2=CC(NCC3=CC=C(Cl)C=C3)=NC4=CC=CC=C24)CC1)(C)C
Biological Activity: Ezurpimtrostat (GNS561) is an orally active PPT1 inhibitor, autophagy inhibitor, immunomodulator, anti-inflammatory agent, and anticancer agent. Ezurpimtrostat inhibits PPT1, dysregulates lysosomal function, redistributes mTOR, and induces apoptosis. Ezurpimtrostat reduces IFN‑α, CRP, immune complex deposition, and SARS‑CoV‑2 viral load. Ezurpimtrostat can be used for the study of systemic lupus erythematosus, SARS‑CoV‑2, hepatocellular carcinoma, fibrosis, and related disorders[1][2][3][4].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Ezurpimtrostat | 99.37% | Ezurpimtrostat (GNS561) is an orally active PPT1 inhibitor, autophagy inhibitor, immunomodulator, anti-inflammatory agent, and anticancer agent. Ezurpimtrostat inhibits PPT1, dysregulates lysosomal function, redistributes mTOR, and induces apoptosis. Ezurpimtrostat reduces IFN‑α, CRP, immune complex deposition, and SARS‑CoV‑2 viral load. Ezurpimtrostat can be used for the study of systemic lupus erythematosus, SARS‑CoV‑2, hepatocellular carcinoma, fibrosis, and related disorders. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Toumi E, et al. GNS561 (ezurpimtrostat), a small basic lipophilic molecule, prevents lupus phenotype in a pristane-induced lupus mouse model. Br J Pharmacol. 2025;182(16):3786-3799. [Content Brief]
- [2]. Bestion E, et al. GNS561 Exhibits Potent Antiviral Activity against SARS-CoV-2 through Autophagy Inhibition. Viruses. 2022;14(1):132. Published 2022 Jan 12. [Content Brief]
- [3]. Brun S, et al. GNS561, a clinical-stage PPT1 inhibitor, is efficient against hepatocellular carcinoma via modulation of lysosomal functions. Autophagy. 2022;18(3):678-694. [Content Brief]
- [4]. Halfon P, et al. Substituted 2,4 diamino-quinoline as new medicament for fibrosis, autophagy and cathepsins b (ctsb), l (ctsl) and d (ctsd) related diseases, EP, EP3620164A1, 2020-03-11.
Keywords
